Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03330561 · ClinicalTrials.gov registry record · Phase 1
PRS-343 in HER2-Positive Solid Tumors
A Phase 1 study, sponsored by Pieris Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT03330561: Completed Phase 1 study, sponsored by Pieris Pharmaceuticals.
NCT03330561 is a Phase 1 study that has completed, run by Pieris Pharmaceuticals. The registered enrollment target is 85 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03330561, a Phase 1 study, has completed, sponsored by Pieris Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
A multi center, open-label, Phase 1 dose escalation study with expansion cohort is designed to determine the MTD, RP2D and dosing schedule of PRS-343 in patients with HER2+ advanced or metastatic solid tumors.
Interventions
- DRUG PRS-343
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2017-09-13 |
| Est. Completion | 2023-12-01 |
| Phase | Phase 1 |
What the finished NCT03330561 record still lists
NCT03330561 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% higher).
The record links to 0 conditions, and to 1 intervention - of which PRS-343 is the first listed.
NCT03330561 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03330561 about?
NCT03330561 is a clinical study titled "PRS-343 in HER2-Positive Solid Tumors". A multi center, open-label, Phase 1 dose escalation study with expansion cohort is designed to determine the MTD, RP2D and dosing schedule of PRS-343 in patients with HER2+ advanced or metastatic solid tumors.
What is the current status of trial NCT03330561?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2017-09-13. Estimated completion is 2023-12-01.
What interventions are being tested in trial NCT03330561?
The interventions under investigation include: PRS-343 (DRUG).
Who is sponsoring clinical trial NCT03330561?
This trial is sponsored by Pieris Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03330561's enrollment target sits among peer trials
85 656th of 2000 higher than 1,342 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI